Jump to content

Search the Community

Showing results for tags 'xtandi'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 19 results

  1. Jim Marshall (not a doctor) said ... If you have castrate-resistant prostate cancer, common treatments that your doctor may add to your regular ADT treatment include: Docetaxel (Taxotere) Enzalutamide (Xtandi) or Abiraterone (Zytiga) Cabazitaxel (Jevtana). But what are your doctor's drug choices when the cancer is no longer under control after all three options? If you responded to docetaxel, your doctor knows you may well respond again to another dosing of docetaxel. But this increases your risk of side effects - especially peripheral neuropathy or nail di
  2. Jim Marshall (not a doctor) said … One of the most important meetings of doctors for men with advanced prostate cancer is the ASCO (American Society of Clinical Oncology) meeting held each year. Yesterday at the ASCO meeting Dr Maha Hussain, on behalf of her team presented the initial results of the PROSPER clinical trial. That trial tested whether men with no metastases, but who had rapidly rising PSA, would do better with early Enzalutamide (Xtandi). This presentation is just the start of scientific reporting. Dr Hussain is presenting this study to hundreds of
  3. Chalkie asks: I am now having to choose between Zytiga and Xtandi. Is there a forum for this? Any suggestions? Jim Marshall (not a doctor) said ... A recent trial for men with metastatic prostate cancer who were no longer responding to ADT alone (mCRPC) showed similar outcomes on both drugs. So, it appears your doctor could recommend either, unless they are worried about how a particular side effect may affect you personally: If you have a health condition that could be made worse by possible seizure or fatigue, your doctor may steer away from Xtandi.
  4. Last Friday 10 March 2017 the Pharmaceutical Benefits Advisory Committee (PBAC) reached its initial decisions on drugs to go onto the PBS at reduced prices. This included whether to put Xtandi (Enzalutamide) before chemo on the PBS. The company will be told of the result next Friday 17 March 2017. If necessary, negotiations between the PBAC and the company continue for 4 weeks. The final results will be published on the PBAC website 21 April 2017. (If the company is not happy with the result, they have until July 2017 to appeal.)
  5. Thank you if you have sent in a submission. Thank you if you have considered sending in a submission, but felt you could not offer much. If you were leaving a submission until the last minute - that is NOW! Help get Xtandi (Enzalutamide) on the PBS for use BEFORE chemotherapy Click on this sentence to go straight to the PBAC to fill out the form. Click this sentence if you wish to see a short YouTube video about this. Click on this sentence to read about the drug and the online form. Closing date for comments is tomorrow Wednesday 8 February 2017 Late submi
  6. Some members needed more technological help to find the form and the video. Here 'tis. Cheers. Jim Help get Xtandi (Enzalutamide) on the PBS for use BEFORE chemotherapy Click on this sentence to go straight to the PBAC to fill out the form. Click this sentence if you wish to see a short YouTube video about this. Click on this sentence to read about the drug and the online form. Closing date for comments is Wednesday 8 February 2017
  7. The opportunity There is a chance to have your voice heard on whether the drug Xtandi (enzalutamide) should be available on the PBS BEFORE chemotherapy. Timing Submissions are due Wednesday 8 February 2017, and no late submissions will be accepted. Enzalutamide on the PBS An important drug for men with advanced prostate cancer is Xtandi, also called enzalutamide. The first evidence that enzalutamide worked looked at using enzalutamide AFTER the chemotherapy drug docetaxel. A committee of experts looked at this evidence. They r
  8. Click here to read Malecare's report of a clinical trial which found that combining Xtandi and Zytiga and using them at the same time was NOT better then either of the drugs by themselves.
  9. Joel Nowak of Malecare reports on an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) Scientific Meeting about how abiraterone (brand name Zytiga) and enzalutamide (brand name Xtandi) may cause cognitive impairment and mood changes. Interestingly the research showed that these side effects were more prevalent with enzalutamide than with abiraterone. Click on this link to read the Malecare report..
  10. You will have noticed that the other members of our Executive Committee (Alan Barlee, Nev Black, Paul Hobson, Tony Maxwell) make an enormous contribution to our monthly phone-in meetings, to information and discussion posted on our website (JimJimJimJim.com), and to general support of our members by phone, email, and at Face-to-a-name members' meetings. What you may not be aware of is that your Executive Committee also spends much time and effort in advocacy duties on behalf of the group. Below are some advocacy events held during the past year. Please be aware that wh
  11. The New Prostate Cancer Infolink has an article about the announcement of a new clinical trial of Enzalutamide (brand name Xtandi) in men with metastatic, hormone-sensitive prostate cancer. This trial will be recruiting men In Australia. The New Prostate Cancer Infolink expresses concern about the suitability of this trial for men newly diagnosed with a significant presence of metastatic disease. Click on this link to read the article.
  12. Respected prostate cancer advocate, Joel Novak from Malecare, believes that Xtandi is superior to Zytiga. Click on this link to read his reasons why he thinks this. Do you agree?
  13. In the United States men with prostate cancer can get access to Abiraterone (brand name Zytiga) and Enzalutamide (brand name Xtandi) before chemotherapy. We'd like to get to a stage in Australia where Abiraterone (brand name Zytiga) and Enzalutamide (brand name Xtandi) are available on the Pharmaceutical Benefits Scheme before chemotherapy. The Australian Pharmaceutical Benefits Advisory Committee, when considering applications to put drugs on the Pharmaceutical Benefits Scheme, looks at what its overseas equivalent bodies have done. Thanks to member Russ for letting us know that
  14. At its November meeting the Pharmaceutical Advisory Committee (PBAC) considered an application to extend the listing of enzalutamide (brand name Xtandi) to include treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have not had prior docetaxel (chemotherapy). The PBAC has released its decision on the application. It is what the PBAC describes as a "1st time decision not to recommend". It's disappointing that the application was not successful but encouraging that the PBAC is asking Astellas to resubmit the application. Here is the full de
  15. Paul Edwards

    New Clinical Trial of JNJ-56021927

    JNJ-56021927 (formerly known as ARN-509) is an androgen receptor antagonist. Some prostate cancer cells require androgens for growth. JNJ-56021927 prevent androgens from binding to the prostate cancer cells’ androgen receptors. JNJ-56021927 is not as advanced in its development as enzalutamide (Brand name Xtandi). Results from initial clinical trials suggest that JNJ-56021927 may be more potent and effective than enzalutamide. A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acet
  16. http://tinyurl.com/pcwv6zd Information in the above reference indicates that the administration of Xofigo/Alpharadin/Radium 223 in company with abiraterone/Zytiga increased the effectiveness of Xofigo as well as overall survival. Combining EBRT (External Beam Radiation Therapy) with Xofigo increased likelihood of bone marrow failure.
  17. PLATO is a 2 stage Clinical Trial with 500 patients (80% in Australia, rest in Finland, UK and USA). On Stage1 everyone gets Enzalutamide (no placebo). [Xtandi is the brand name for Enzalutamide] Those continuing in Stage 2 are randomised: 50% of patients to Abiraterone plus placebo and 50% of patients to Abiraterone plus Enzalutamide. Both arms in Stage 2 also get Prednisone to go with the Abiraterone. Stage 2 is double blind so neither doctor or patient know which arm you are in. Also in Stage 2 they do not do PSA tests but track the tumour w
  18. AR-V7 is an androgen receptor variant which, if found in the blood stream, disables the effectiveness of either Xtandi/enzalutamide or Zytiga/abiraterone acetate. I have prepared a summary of recent research about AR-V7 which is available at http://tinyurl.com/qbgpezo [Ed - Chuck's paper mentions blood tests for Circulating Tumour Cells (CTC) and AR-V7. These tests are not routinely available in Australia.]
  19. Thanks to Chuck Maack for drawing our attention to the report of a recent presentation by Dr Oliver A Sartor who was the principal North American investigator for the clinical trial that led to the approval by the United States Food and Drug Administration (FDA) for radium 223 (brand name Xofigo). In 2013 the FDA approved radium 223 for treatment for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Dr Sartor said that determining whether or not a patient had symptoms of bone metastases could often be a grey area.
×
×
  • Create New...